Site Meter How the World Health Organization is Helping to Prevent a Catastrophic H5N1 Flu Pandemic | UN Dispatch
Increase Font Size Decrease Font Size

How the World Health Organization is Helping to Prevent a Catastrophic H5N1 Flu Pandemic

(World Health Organization HQ, Geneva)  – H5N1 influenza is what keeps people here up at night.  The flu strain is deadly to humans on an order of magnitude greater than any other flu virus in history, including the Spanish flu pandemic of 1918.  It kills approximately 60% of the people it infects.  Just to put that figure in perspective: seasonal flu kills about 0.1% of the people it infects; Spanish Flu killed about 2.5% of people infected.

“Outbreak of influenza is the most worrisome thing,” says Dr Keiji Fukuda the Assistant Director-General for Health Security and Environment at the World Health Organization. “H5n1 is almost a unique virus. Very few viruses are capable of killing like that.”

So far, the virus has only infected humans who have caught it from infected animals, mostly poultry. It has not made the jump from human-to-human transmission.  Humanity has time to prepare and respond. That’s where the World Health Organization comes in.

The first task is worldwide monitoring of suspected cases. Everyday, all day, staffers at the WHO’s operations center monitor media reports and sort through information sent to them from national health ministries. When a case might be credible, staff alerts a network of health workers,  setting into motion a series of procedures along pre-established guidelines.

This system, called the “International Health Regulations” was created in response to the 2003 SARS outbreak. Members of the WHO, which include every UN member state, realized that ad hoc response to the SARS outbreak undermined the international community’s’ ability to effectively create a coordinated, international response the SARS outbreak. So, when the dust settled two years later member states created this system for monitoring and responding to global health emergencies.

The International Health Regulations range from expediting visa requests for foreign epidemiologists, to setting up secure phone lines to share sensitive information across governments, to establishing protocol for the hygienic burying of victims.  From a political standpoint, the fact that every country has bought into this system means that the response can truly be global.

This brings us to monitoring and response to H5N1.  The last case detected and reported through WHO’s monitoring system occurred in Indonesia, about 10 days ago. The victim was a two year old boy whose parents are quail egg vendors. A week earlier, Egyptian authorities alerted the WHO to a suspected case of H5N1 that killed a 26 year old women.  In Egypt, the US Centers for Disease Control provided some technical support to local officials through its regional office, per the IHR. Also according to the IHR, the World Health Organization updates the private sector and scientific bodies (like the US National Institutes for Health) about latest strains so that potential vaccines can be developed.

Two recent scientific studies demonstrated that H5N1 can develop a mutation enabling its transmission between humans. That mutation has only been created in laboratories, and has not yet occurred in nature. If and when it does, the world will turn to the World Health Organization to contain the outbreak and manage a global response.

Preventing the apocalyptic outbreak of H5N1 is just one of many reasons why we need a strong World Health Organization.


  • dfedson

    The debate over restricting publication
    of the experimental details of the H5N1 research by Fouchier and Kawaoka misses
    a larger point. Influenza viruses can and do develop more efficient
    transmissibility on their own; we’ve known this for decades. What’s more
    important is to understand what we might do to reduce mortality when this
    happens. Immunomodulatory agents could probably be used to modify the host
    response to severe influenza and improve survival (Influenza Other Respi Virus
    2009; 3: 129-42). Evidence that this happens was published recently. In a study
    of patients hospitalized with laboratory-confirmed influenza, statin treatment
    reduced mortality by 41% (J Infect Dis 2012; 205: 13-9). The reduction in
    mortality was in addition to any benefit that might have been due to previous
    influenza vaccination or antiviral treatment. Influenza scientists and the
    public health officials, including those at WHO, have yet to understand the potential
    importance of these agents, yet if a highly virulent H5N1 virus gets loose, the
    vaccines and antivirals they’re counting on won’t arrive in time to do
    much good. The issue we should be discussing is not whether to undertake or
    publish research on H5N1 influenza virus transmission; it’s why we have failed
    to undertake laboratory and clinical research on immunomodulatory agents that
    could save lives. These agents are produced as generics in developing countries
    and could be used to treat anyone with access to basic health care. The cost of
    treating an individual patient would be less than one dollar. WHO has yet to use its “bully pulpit” to demand, on behalf of developing countries, that this research be undertaken immediately. 

Diplo Tweets